The Neuroprotective Effect of Xanthone and 6-Hydroxyflavone in the Model of Parkinson's Disease Induced by 6-Hydroxydopamine in Laboratory Mice: Behavioral Evaluations

Subject Areas : Journal of Animal Biology

Mahshid  Attari ¹ (Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran)
Maryam  Khosravi ² (Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran)
Ramin  Hajikhani ³ (Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran)
Maryam  Bananaj ⁴ (Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran)
Jalal  Solati ⁵ (Department of Biology, Karaj branch, Islamic Azad University, Alborz, Iran)

Received: 2021-05-03 Accepted : 2022-11-03 Published : 2023-02-20

Keywords: Parkinson's disease, 6-Hydroxcy Dopamine, Xanthone, 6-Hydroxyflovane, Laboratory Mouse,

Abstract :

Oxidative stress and neuroinflammation play a role in Parkinson's disease. Antioxidants and anti-inflammatories such as polyphenol compounds and flavonoids inhibit neuronal death. The aim of the present study is the effect of xanthone and 6-hydroxyflavone in Parkinson's disease in laboratory mice. Animals are cannulated by stereotaxic surgery and unilateral injection of 6-hydroxy-dopamine is performed in the dense area of ​​the substantia nigra (SNc) of the brain. Xanthone and 6-hydroxyflavone were injected intraperitoneally. Three weeks after surgery, movement evaluations and pseudo-anxiety and pseudo-depression behaviors were performed. Counting of all the neurons in the dense area of ​​the substantia nigra was done. Injection of 6-hydroxydopamine increased the number of apomorphine rotations. Catalysis time increased. Neurons in the substantia nigra decreased. 6-Hydroxyflavone (50 and 100 mg/kg) and xanthone (100 and 200 mg/kg) reduced vertigo and catalepsy. In the elevated plus shape maze test, 6-hydroxyflavone in doses of 25 and 50 mg/kg and xanthone in doses of 50 and 100 mg/kg increased motor activity. In the forced swimming test, xanthone in doses of 50, 100 and 200 mg/kg reduced immobility in parkinsonian rats. The number of substantia nigra neurons increased with the treatment of 6-hydroxyflavone in doses of 50 and 100 mg/kg and 200 mg/kg xanthone. Xanthone and 6-hydroxyflavone improved movement disorder and catalepsy and increased the number of nerve cells in the substantia nigra. Xanthon was able to reduce depression. Probably, part of these central protective effects are mediated by the antioxidant and anti-inflammatory effects of xanthone and 6-hydroxyflavone, which prevent cell death by reducing free radicals and inflammatory cytokines, and as a result, they improve cognitive and movement disorders.

References:

1. Attari M., Jamaloo F., Shadvar S., Fakhraei N., Dehpour A.R. 2016. Effect of Withania somnifera dunal root extract on behavioral despair model in mice: a possible role for nitric oxide. Acta Medica Iranica, 54(3):165-172.


2. Bumrungpert A., Kalpravidh R.W., Chuang C.C., Overman A., Martinez K., Kennedy A., McIntosh M. 2010. Xanthones from mangosteen inhibit inflammation in human macrophages and in human adipocytes exposed to macrophage-conditioned media. The Journal of Nutrition, 140(4):842-847.


3. Catorce M.N., Acero G., Pedraza-Chaverri J., Fragoso G., Govezensky T., Gevorkian G. 2016. Alpha-mangostin attenuates brain inflammation induced by peripheral lipopolysaccharide administration in C57BL/6J mice. Journal of Neuroimmunology, 297:20-27.


4. Chin Y.W., Jung H.A., Chai H., Keller W.J., Kinghorn A.D. 2008. Xanthones with quinone reductase-inducing activity from the fruits of Garcinia mangostana (Mangosteen). Phytochemistry, 69(3):754-758.


5. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E., Canteras N.S., Da Cunha C. 2005. Comparison of bilaterally 6-OHDA-and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. Journal of Neuroscience Methods, 148(1):78-87.


6. Ghaffari F., Moghaddam A.H., and Zare M. 2018. Neuroprotective effect of quercetin nanocrystal in a 6-hydroxydopamine model of parkinson disease: biochemical and behavioral evidence. Basic and Clinical Neuroscience, 9(5):317.


7. Gupta S.C., Tyagi A.K., Deshmukh-Taskar P., Hinojosa M., Prasad S., Aggarwal B.B. 2014. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Archives of Biochemistry and Biophysics, 559:91-99.


8. Haghdoost-Yazdi H., Sehatbakhsh S., Sophiabadi M., Dargahi T., Yaghubidust M.H., Piri H. 2016. Effect of potassium channel blocker Tetraethylammonium pretreatment on prevention of the 6-OHDA-induced chronic Parkinson's disease in rats. The journal of Gazvin University of Medical Sciences, 20(2):41-48.


9. Jenner P. 2003. Oxidative stress in Parkinson's disease. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 53(S3):S26-S38.


10. Joseph J.A., Shukitt-Hale B., Denisova N.A., Bielinski D., Martin A., McEwen J.J., Bickford P.C. 1999. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. Journal of Neuroscience, 19(18):8114-8121.


11. Khoshnoodi M., Fakhraei N., Dehpour A.R. 2015. Possible involvement of nitric oxide in antidepressant-like effect of silymarin in male mice. Pharmaceutical Biology, 53(5):739-745.


12. Liu Q., Li D., Wang A., Dong Z., Yin S., Zhang Q., Ye Y., Li L., Lin L. 2016. Nitric oxide inhibitory xanthones from the pericarps of Garcinia mangostana. Phytochemistry, 131:115-123.


13. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., Khan I., Netzer W.J., Xu H., Butko P. 2002. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proceedings of the National Academy of Sciences, 99(19):12197-12202.


14. Maciel R.M., Carvalho F.B., Olabiyi A.A., Schmatz R., Gutierres J.M., Stefanello N., Zanini D., Rosa M.M., Andrade C.M., Rubin M.A., Schetinger M.R. 2016. Neuroprotective effects of quercetin on memory and anxiogenic-like behavior in diabetic rats: Role of ectonucleotidases and acetylcholinesterase activities. Biomedicine and Pharmacotherapy, 84:559-568.


15. Macready A.L., Kennedy O.B., Ellis J.A., Williams C.M., Spencer J.P., Butler L.T. 2009. Flavonoids and cognitive function: a review of human randomized controlled trial studies and recommendations for future studies. Genes and Nutrition, 4(4):227-242.


16. Mahabusarakam W., Wiriyachitra P., Taylor W.C., 1987. Chemical constituents of Garcinia mangostana. Journal of Natural Products, 50(3):474-478.


17. Mahabusarakam W., Proudfoot J., Taylor W., Croft K. 2000. Inhibition of lipoprotein oxidation by prenylated xanthones derived from mangostin. Free Radical Research, 33(5):643-659.


18. Mishra M., Sonar P., Tripathi A., Saraf S., Verma S. 2020. Ligand and structure-based hybrid screening for anti-Parkinson agents and their pharmacological evaluation. International Journal of Pharmaceutical Education and Research, 2(02):30-38.


19. Mousavi M.S., Riazi G., Imani A., Meknatkhah S., Fakhraei N., Pooyan S., Tofigh N. 2019. Comparative evaluation of adolescent repeated psychological or physical stress effects on adult cognitive performance, oxidative stress, and heart rate in female rats. Stress, 22(1):123-132.


20. Mura A., Feldon J. 2003. Spatial learning in rats is impaired after degeneration of the nigrostriatal dopaminergic system. Movement disorders: official journal of the Movement Disorder Society, 18(8):860-871.


21. Paladini A.C., Marder M., Viola H., Wolfman C., Wasowski C., Medina J.H. 1999. Flavonoids and the central nervous system: from forgotten factors to potent anxiolytic compounds. Journal of Pharmacy and Pharmacology, 51(5):519-526.


22. Pedraza-Chaverri J., Cárdenas-Rodríguez N., Orozco-Ibarra M., Pérez-Rojas J.M. 2008. Medicinal properties of mangosteen (Garcinia mangostana). Food and Chemical Toxicology, 46(10):3227-3239.


23. Pedraza-Chaverrí J,. Reyes-Fermín L.M., Nolasco-Amaya E.G., Orozco-Ibarra M., Medina-Campos O.N., González-Cuahutencos O., Rivero-Cruz I., Mata R. 2009. ROS scavenging capacity and neuroprotective effect of α-mangostin against 3-nitropropionic acid in cerebellar granule neurons. Experimental and Toxicologic Pathology, 61(5):491-501.


24. Peres V., Nagem T.J., de Oliveira F.F. 2000. Tetraoxygenated naturally occurring xanthones. Phytochemistry, 55(7):683-710.


25. Pienaar I.S., Chinnery P.F. 2013. Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression. Pharmacology and Therapeutics, 137(1):1-21.


26. Prinssen E.P., Colpaert F.C., and Koek W. 2002. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. European Journal of Pharmacology, 453(2-3):217-221.


27. Ramassamy C. 2006. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. European Journal of Pharmacology, 545(1):51-64.


28. Schober 2004. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell and Tissue Research, 318(1):215-224.


29. Spencer J.P. 2010. The impact of fruit flavonoids on memory and cognition. British Journal of Nutrition, 104(S3):S40-S47.


30. Sriraksa N., Wattanathorn J., Muchimapura S., Tiamkao S., Brown K., Chaisiwamongkol K. 2012. Cognitive-enhancing effect of quercetin in a rat model of Parkinson's disease induced by 6-hydroxydopamine. Evidence-Based Complementary and Alternative Medicine, 2012:1-10


31. Suzuki O., Katsumata Y., Oya M., Chari V.M., Klapfenberger R., Wagner H., Hostettmann K., 1980. Inhibition of type A and type B monoamine oxidase by isogentisin and its 3-o-glucoside. Planta Medica, 39 (05):19-23.


32. Suzuki K., Okada K., Wakuda T., Shinmura C., Kameno Y., Iwata K., Takahashi T., Suda S., Matsuzaki H., Iwata Y., Hashimoto K., 2010. Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine. Plos one, 5(2):e9260.


33. Tansey M.G. and Goldberg M.S., 2010. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiology of Disease, 37(3):510-518.


34. Tiang N., Ahad M.A., Murugaiyah V., Hassan Z. 2020. Xanthone‐enriched fraction of Garcinia mangostana and α‐mangostin improve the spatial learning and memory of chronic cerebral hypoperfusion Journal of Pharmacy and Pharmacology, 72(11):1629-1644.


35. Ungerstedt U. 1971. Postsynaptic supersensitivity after 6‐hydroxy‐dopamine induced degeneration of the nigro‐striatal dopamine system. Acta Physiologica Scandinavica, 82(S367):69-93.


36. Weecharangsan W., Opanasopit P., Sukma M., Ngawhirunpat T., Sotanaphun U., Siripong P. 2006. Antioxidative and neuroprotective activities of extracts from the fruit hull of mangosteen (Garcinia mangostana). Medical Principles and Practice, 15(4):281-287.


37. Williams R.J., Spencer J.P. 2012. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radical Biology and Medicine, 52(1):35-45.


38. Xie Z., Sintara M., Chang T., Ou B. 2015. Daily consumption of a mangosteen‐based drink improves in vivo antioxidant and anti‐inflammatory biomarkers in healthy adults: a randomized, double‐blind, placebo‐controlled clinical trial. Food Science and Nutrition, 3(4):342-348.


39. Youdim K.A., Joseph J.A. 2001. A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects. Free Radical Biology and Medicine, 30(6):583-594.


40. Zhao B. 2009. Natural antioxidants protect neurons in Alzheimer’s disease and Parkinson’s disease. Neurochemical Research, 34(4):630-638.